What is the recommended treatment for an 80‑plus‑year‑old woman with grade 2 invasive lobular carcinoma?

Treatment for Grade 2 Invasive Lobular Carcinoma in an 80+ Year-Old Woman

For an 80+ year-old woman with grade 2 invasive lobular carcinoma, treatment should include surgical resection (mastectomy preferred over breast-conserving surgery due to higher local recurrence rates in ILC) followed by endocrine therapy, with full-dose systemic therapy used whenever feasible despite advanced age 1.

Surgical Management

Primary Surgery Considerations

The surgical approach for invasive lobular carcinoma requires special attention due to its unique growth pattern:

• Mastectomy is generally safer than breast-conserving surgery for ILC, as local recurrence rates after breast conservation remain high (up to 48% requiring completion mastectomy) even with clear margins and post-operative radiotherapy 2
• ILC's discohesive, single-file growth pattern makes achieving adequate margins more challenging 3, 4
• If breast-conserving surgery is attempted, MRI should be used for preoperative staging to improve accuracy of tumor extent assessment 5
• Sentinel lymph node biopsy is appropriate for axillary staging unless clinical node involvement is suspected 1

Age-Specific Surgical Considerations

In elderly patients, full doses of drugs should be used whenever feasible 1. Age alone should not preclude effective treatment that could improve quality of life or provide survival benefit 6.

Radiation Therapy

Post-operative radiation decisions depend on surgical approach:

• After mastectomy: Radiation is indicated if ≥4 positive nodes or T3-T4 tumors; consider for 1-3 positive nodes especially if young or medially located 7
• After breast-conserving surgery: Whole breast radiation is strongly recommended and reduces local recurrence by two-thirds 1
• For women >70 years with stage I, ER-positive disease, pT1N0 with clear margins: Radiation may be omitted if receiving endocrine therapy, though local recurrence increases from 2% to 10% at 10 years 6

Systemic Therapy

Endocrine Therapy (Primary Treatment)

ILC is typically ER-positive and strongly favors endocrine therapy due to low chemosensitivity 3, 4:

For postmenopausal women:

• Aromatase inhibitors (anastrozole 1 mg daily, exemestane 25 mg daily, or letrozole 2.5 mg daily) for 5 years are preferred first-line options 8, 9
• Tamoxifen 20 mg daily for 5 years is an alternative if aromatase inhibitors are contraindicated 10, 11
• Raloxifene 60 mg daily is another option but less commonly used for treatment 10

Key monitoring requirements:

• Baseline bone density evaluation before starting aromatase inhibitors 1
• Regular bone density monitoring during AI therapy 1
• Consider bisphosphonates or RANKL inhibitors if moderate bone loss develops 8
• Routine lipid profile monitoring 1
• For tamoxifen: annual gynecological examination 1

Chemotherapy Considerations

• Chemotherapy is generally NOT recommended for grade 2 ILC unless high-risk features are present (≥4 positive nodes, or 1-3 positive nodes with ER/PR-negative or HER2-positive disease) 9
• ILC demonstrates lower pathological response rates to chemotherapy compared to ductal carcinoma 3, 4
• Treatment decisions should be based on molecular subtype rather than histology alone 5

Follow-Up Surveillance

Specific considerations for ILC:

• Regular visits: every 3-4 months for first 2 years, every 6 months years 3-5, then annually 1
• Annual mammography with ultrasound (ultrasound is particularly important for ILC follow-up due to its subtle imaging characteristics) 1, 12
• For women with life expectancy <5 years, routine mammographic surveillance may cause more harm than benefit 6
• No routine laboratory or imaging tests (bone scans, CT, tumor markers) in asymptomatic patients 1
• Blood tests only to monitor endocrine therapy side effects 1

Important Caveats

ILC-Specific Challenges

• ILC is notoriously difficult to detect on imaging due to its infiltrative growth pattern 3, 12
• Consider MRI for surveillance given ILC's subtle presentation 12
• Late recurrences can occur - one case report documented gastric metastasis 14 years after initial treatment 13
• ILC can present with unusual metastatic patterns including gastrointestinal involvement 13

Genetic Testing

• CDH1 mutation analysis should be included in genetic testing for patients with ILC 5
• Consider risk-reducing strategies if germline mutations identified

Quality of Life Measures

• Encourage regular exercise (provides functional and psychological benefits) 1
• Nutritional counseling for weight management 1
• Avoid hormone replacement therapy - increases recurrence risk 1

The treatment approach prioritizes endocrine therapy given ILC's typical hormone receptor-positive biology and poor chemotherapy response, while recognizing that age alone should not limit appropriate surgical and systemic treatment options.